The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo

Radiomics Analysis of 177Lu-PSMA I&T Radioligand Therapy Dosimetry in a Castration Resistant Metastatic Prostate Cancer Patient

Author(s): Eve Kelk *

Pp: 424-429 (6)

DOI: 10.2174/9781681088655122010039

* (Excluding Mailing and Handling)


177Lu-DOTAGA-(l-y)fk(Sub-KuE) (177Lu-PSMA I&T) is currently used for
radioligand therapy (RLT) of metastatic castration-resistant prostate cancer (mCRPC)
in several centers in Europe. It was launched in Tallinn, Estonia, in December 2018. As
an additional project, a model of dosimetric analysis was created, utilizing voxel-based
dosimetry and intra-lesion radiomics to assess their practicality in routine dosimetry
[1]. This was a successful project, and the work is summarized in this chapter.

Keywords: 177Lu isotope, Dosimetry, Positron emission tomography, Prostate cancer, PSMA, Quantitative SPECT, Radiomics, Radionuclide therapy, Voxelbased dosimetry.

Related Journals
Related Books
© 2024 Bentham Science Publishers | Privacy Policy